Publicaciones en colaboración con investigadores/as de Charité (10)

2023

  1. Quantitative flow ratio versus fractional flow reserve for guiding percutaneous coronary intervention: design and rationale of the randomised FAVOR III Europe Japan trial

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 16, pp. e1358-e1364

2019

  1. Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment

    Journal of the American College of Cardiology, Vol. 73, Núm. 4, pp. 444-453

  2. Comparison of Major Adverse Cardiac Events between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients with or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial

    JAMA Cardiology, Vol. 4, Núm. 9, pp. 857-864

  3. Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserve–Guided Revascularization Strategy

    JACC: Cardiovascular Interventions, Vol. 12, Núm. 20, pp. 2035-2046

2018

  1. Pre-Angioplasty Instantaneous Wave-Free Ratio Pullback Predicts Hemodynamic Outcome In Humans With Coronary Artery Disease: Primary Results of the International Multicenter iFR GRADIENT Registry

    JACC: Cardiovascular Interventions, Vol. 11, Núm. 8, pp. 757-767

  2. Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes

    JACC: Cardiovascular Interventions, Vol. 11, Núm. 15, pp. 1437-1449

  3. The Experts “Live” Workshop of the EuroCTO Club 2017, Berlin

    EuroIntervention

2017

  1. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI

    New England Journal of Medicine, Vol. 376, Núm. 19, pp. 1824-1834

2015

  1. Coronary vascular regulation, remodelling, and collateralization: Mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation

    European Heart Journal, Vol. 36, Núm. 45, pp. 3134-3146

1992

  1. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial

    Circulation, Vol. 86, Núm. 1, pp. 100-110